Company Overview - Balchem Corporation is a leading provider of specialty ingredients and performance products, with over $1.0 billion in trailing twelve-month revenue and a diversified customer base [6] - The company utilizes advanced encapsulation and formulation technologies to deliver differentiated solutions for nutrition, health, and industrial markets [6] - Balchem's product portfolio includes microencapsulated nutrients, food and beverage systems, and sterilization agents, serving various sectors such as food, pharmaceuticals, and animal health [8] Financial Performance - For the year 2025, Balchem reported record net sales of $1 billion, an increase of 8.8%, and net earnings of $154.8 million, up 20.5% [10] - Adjusted EBITDA reached $274.9 million, and free cash flow hit a record $173.6 million [10] - The company maintained a gross margin of 35.6% in the fourth quarter despite input cost pressures [10] Market Position - As of February 17, 2026, Balchem's shares were priced at approximately $180, reflecting an 8% increase over the past year, which is lower than the S&P 500's 16% gain [7] - Balchem represents 1.6% of Harvey Partners' 13F reportable AUM of $1.13 billion, indicating a strategic addition to the fund's portfolio [7] - The company has a solid balance sheet, with cash at $74.6 million and net debt leverage at just 0.3 times adjusted EBITDA [11] Investment Appeal - The addition of Balchem to a portfolio primarily focused on cyclical industrial and equipment names provides a steady compounder with durable growth potential tied to nutrition and health trends [9][12] - The company's strong competitive position within the specialty chemicals sector is supported by its pricing power and recurring demand [12]

Core Insights - Balchem, a leader in specialty ingredients for food, pharmaceutical, and animal health markets, reported significant insider selling activity by Director David B Fischer [1][2]. Transaction Summary - On December 3, 2025, David B Fischer sold 8,000 common shares for a total of $1,231,748.20, following the exercise of 6,000 fully vested options [2][3]. - Post-transaction, Fischer's direct share count decreased by 50%, from 15,989 to 7,989 shares, representing approximately 0.025% of shares outstanding [6]. - The weighted average sale price was $153.97, closely aligning with the market closing price of $156.2 on December 12, 2025 [6]. Company Overview - Balchem reported a total revenue of $1.01 billion and a net income of $149.2 million for the trailing twelve months (TTM) [5]. - The company has a dividend yield of 0.61% and experienced a 1-year price change of -12.4% [5]. Business Operations - Balchem specializes in providing ingredients for human nutrition, animal nutrition, and specialty industrial applications, including microencapsulated nutrients and sterilization agents [7]. - The company serves various sectors, including food and beverage manufacturers, pharmaceutical companies, and agricultural businesses, both domestically and internationally [7]. Strategic Initiatives - Balchem is investing in growth by building a new facility for producing microencapsulated food ingredients and nutraceuticals, which will more than double its current capacity [11]. - This investment is a response to increasing demand, indicating potential for continued business growth [12]. Recent Developments - Following the insider selling, Balchem announced a 10.3% dividend increase, marking the 17th consecutive annual dividend increase [10]. - The company also reported record quarterly sales, which increased by 11.5% year over year [11].